RESOURCES for your practice and your patients

Information to help your Practice

Onychomycosis culturing tips

Best Practices for Nail Cultures

Proper collection is the first step in a successful onychomycosis diagnosis.
This card offers quick tips.

Download

Important Information About Coding and Billing

From consistent coding to detailed documentation, this guide helps ensure
that you are properly reimbursed for the diagnosis of onychomycosis.1,2

Download

Navigating the Prior Authorization Process With JUBLIA

Many prior authorizations are denied due to missing documentation.
This resource will help you better understand payer requirements.

Download

How to Help Your Patients Adhere to Treatment

Your patients have started treatment. But how can you help ensure they'll
complete it? This tool reveals how you can help patients stay on track.

Download

Important information to share with your patients

For patients just starting on JUBLIA, here is some useful information to share when they are in your office3:

  • JUBLIA is a prescription medicine used on the skin and nail (topical) to treat toenail fungus in people 18 years of age and older. It is not known if JUBLIA is safe and effective in children.
  • JUBLIA should be applied to affected toenails 1 time each day for 48 weeks.
  • Wait for at least 10 minutes after showering, bathing, or washing before applying.
Helpful patient brochure

Helpful Patient Brochure

This brochure contains information on onychomycosis, risk factors, and how JUBLIA works.

Download

Useful patient information sheet

Useful Patient Information Sheet

This document provides patients with information on onychomycosis and on how to use JUBLIA properly to get the most out of their treatment. Give one of these to your patients any time you prescribe JUBLIA.

Download

Indication

JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Important Safety Information

  • JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
  • Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
  • The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
  • JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see JUBLIA Prescribing Information.

References: 1. Block BH. Avoiding That Medicare Audit. Podiatry Management Online. http://www.podiatrym.com/pm%5CAvoid.pdf. Accessed February 5, 2018. 2. Department of Health and Human Services. Centers for Medicare & Medicaid Services. Evaluation and Management Services. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/eval-mgmt-serv-guide-ICN006764.pdf . Accessed February 5, 2018. 3. JUBLIA [prescribing information.] Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2016.

INDICATION

JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Please see JUBLIA Prescribing Information.

IMPORTANT SAFETY INFORMATION

  • JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.
  • Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.
  • The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).
  • JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.